<p><strong>Lakewood-Amedex Biotherapeutics Inc. (LABT)</strong> 的股票周一交易上涨，但随后反转并开始下跌，此前该公司公布了 Nu-3 的数据。</p>
<ul>
<li>Lakewood-Amedex 股票正在测试关键支撑位。LABT 走弱的原因是什么？</li>
</ul>
<h2>Lakewood-Amedex 强调 Nu-3 的制造进展</h2>
<p>Lakewood-Amedex 表示，Nu-3 正在开发为一种局部给药的治疗方法，旨在减少轻度感染的糖尿病足溃疡的抗微生物耐药风险。</p>
<p>该公司表示，已根据当前良好生产规范（cGMP）指南完成了多个多公斤规模的制造运行，效率很高。Lakewood-Amedex 还表示，工艺开发的进展改善了商品成本，并生产出具有增强物理化学特性的原料药。</p>
<p>此外，该公司表示，Nu-3 胶体配方的多公斤数量已在 cGMP 指南下制造，适合用于临床试验。</p>
<p>“Lakewood-Amedex Biotherapeutics (LABT) 一直在努力优化生产所需的配方和制造工艺，以生产 Bisphosphocin 药物原料和药品，” 首席执行官 <strong>Kelvin Cooper</strong> 说。</p>
<p>Cooper 表示，Bisphosphocin 类化合物可能适应多种药物产品配方和给药方法，包括在复杂尿路感染和肺部感染中的潜在应用。</p>
<p>该公司还宣布，稳定性测试表明，Nu-3 原料药材料在至少五年内保持稳定，而 Nu-3 药品配方在至少两年内保持稳定。</p>
<p>Lakewood-Amedex 表示，初步的生物负荷和抗微生物有效性测试显示，在至少两年内未检测到生物负荷水平，并且产品不需要额外的防腐剂来维持抗微生物有效性。</p>
<p><strong>另请阅读：今日股市：在阿联酋核电站袭击后，道琼斯、标准普尔 500、纳斯达克期货下跌——Regeneron Pharma、NextNRG、ServiceNow 备受关注（更新）</strong></p>
<h2>Lakewood-Amedex 股票下跌</h2>
<p><strong>LABT 价格动态：</strong> 根据 Benzinga Pro 的数据，截至发布时，Lakewood-Amedex 股票交易下跌 22.67%，报 $1.15。</p>
<p><em>图片来源于 Shutterstock</em></p>

LABT

<p>Lakewood-Amedex Biotherapeutics Inc.（纳斯达克代码：LABT）股价下跌 22.67%，至 1.15 美元，尽管该公司宣布了其针对糖尿病足溃疡的 Nu-3 治疗的积极生产更新。公司报告了成功的多公斤规模生产运行和稳定性测试结果，表明该产品的长期稳定性和有效性。然而，股价逆转了早前的涨幅，目前正在测试关键支撑位</p>

<p><strong>Lakewood-Amedex Biotherapeutics Inc. ( LABT )</strong> shares were trading higher Monday but have since reversed and begun trading lower after the company announced data for Nu-3.</p>
<div class="lb-trans"><p><strong>Lakewood-Amedex Biotherapeutics Inc. (LABT)</strong> 的股票周一交易上涨，但随后反转并开始下跌，此前该公司公布了 Nu-3 的数据。</p>
</div><ul>
<li>Lakewood-Amedex stock is testing key support levels. What’s behind LABT weakness?</li>
</ul>
<div class="lb-trans"><ul>
<li>Lakewood-Amedex 股票正在测试关键支撑位。LABT 走弱的原因是什么？</li>
</ul>
</div><h2>Lakewood-Amedex Highlights Manufacturing Progress For Nu-3</h2>
<div class="lb-trans"><h2>Lakewood-Amedex 强调 Nu-3 的制造进展</h2>
</div><p>Lakewood-Amedex said Nu-3 is being developed as a topically delivered treatment for mildly infected diabetic foot ulcers designed to reduce the risk of antimicrobial resistance.</p>
<div class="lb-trans"><p>Lakewood-Amedex 表示，Nu-3 正在开发为一种局部给药的治疗方法，旨在减少轻度感染的糖尿病足溃疡的抗微生物耐药风险。</p>
</div><p>The company said it completed several multikilogram-scale manufacturing runs for members of its Bisphosphocin class of compounds under current Good Manufacturing Practices guidelines with high efficiency. Lakewood-Amedex also said process development advances improved cost of goods and produced bulk drug substance with enhanced physical chemistry characteristics.</p>
<div class="lb-trans"><p>该公司表示，已根据当前良好生产规范（cGMP）指南完成了多个多公斤规模的制造运行，效率很高。Lakewood-Amedex 还表示，工艺开发的进展改善了商品成本，并生产出具有增强物理化学特性的原料药。</p>
</div><p>In addition, the company said multikilogram quantities of the Nu-3 gel formulation have been manufactured under cGMP guidelines and are suitable for use in clinical trials.</p>
<div class="lb-trans"><p>此外，该公司表示，Nu-3 胶体配方的多公斤数量已在 cGMP 指南下制造，适合用于临床试验。</p>
</div><p>&#34;Lakewood-Amedex Biotherapeutics ( LABT ) has worked diligently to optimize formulation and manufacturing processes required to produce both the Bisphosphocin drug substances and drug products,&#34; said CEO <strong>Kelvin Cooper</strong>.</p>
<div class="lb-trans"><p>“Lakewood-Amedex Biotherapeutics (LABT) 一直在努力优化生产所需的配方和制造工艺，以生产 Bisphosphocin 药物原料和药品，” 首席执行官 <strong>Kelvin Cooper</strong> 说。</p>
</div><p>Cooper said the Bisphosphocin class of compounds could potentially be adapted to a range of drug product formulations and delivery methods, including possible applications in complicated urinary tract infections and pulmonary infections.</p>
<div class="lb-trans"><p>Cooper 表示，Bisphosphocin 类化合物可能适应多种药物产品配方和给药方法，包括在复杂尿路感染和肺部感染中的潜在应用。</p>
</div><p>The company also announced that stability testing showed the Nu-3 bulk drug substance material remained stable for at least five years, while the Nu-3 drug product formulation remained stable for at least two years.</p>
<div class="lb-trans"><p>该公司还宣布，稳定性测试表明，Nu-3 原料药材料在至少五年内保持稳定，而 Nu-3 药品配方在至少两年内保持稳定。</p>
</div><p>Lakewood-Amedex said initial testing for bioburden and antimicrobial effectiveness demonstrated undetectable bioburden levels for at least two years and showed the product does not require additional preservatives to maintain antimicrobial effectiveness.</p>
<div class="lb-trans"><p>Lakewood-Amedex 表示，初步的生物负荷和抗微生物有效性测试显示，在至少两年内未检测到生物负荷水平，并且产品不需要额外的防腐剂来维持抗微生物有效性。</p>
</div><p><strong>Read Also: Stock Market Today: Dow, S&amp;P 500, Nasdaq Futures Drop After UAE Nuclear Plant Strike— Regeneron Pharma, NextNRG, ServiceNow In Focus (UPDATED)</strong></p>
<div class="lb-trans"><p><strong>另请阅读：今日股市：在阿联酋核电站袭击后，道琼斯、标准普尔 500、纳斯达克期货下跌——Regeneron Pharma、NextNRG、ServiceNow 备受关注（更新）</strong></p>
</div><h2>Lakewood-Amedex Shares Fall</h2>
<div class="lb-trans"><h2>Lakewood-Amedex 股票下跌</h2>
</div><p><strong>LABT Price Action:</strong> At the time of publication, Lakewood-Amedex shares are trading 22.67% lower at $1.15, according to data from Benzinga Pro.</p>
<div class="lb-trans"><p><strong>LABT 价格动态：</strong> 根据 Benzinga Pro 的数据，截至发布时，Lakewood-Amedex 股票交易下跌 22.67%，报 $1.15。</p>
</div><p><em>Image via Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源于 Shutterstock</em></p>
</div>

尽管 Nu-3 制造更新积极，Lakewood-Amedex 的股票仍然下跌